AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤AN2-504661 nominated as development candidate for hypophosphatasia
- ➤Novel oral ENPP1 inhibitor shows potent, selective inhibition and animal-model efficacy
- ➤Phase 1 study planned for second half of 2027
- ➤Candidate demonstrates favorable pharmacokinetics, oral bioavailability, and encouraging safety profile
Expert Statements
Vince Hernandez, Senior Vice President of Research & Head of Chemistry of AN2 Therapeutics
“The selection of AN2-504661 as a development candidate represents an important milestone for our ENPP1 program and further validates the potential of our boron chemistry platform to address challenging biological targets.”
Vince Hernandez, Senior Vice President of Research & Head of Chemistry of AN2 Therapeutics
“We believe ENPP1 represents a compelling target with the potential to address underlying disease biology in hypophosphatasia and are encouraged by the opportunity to provide an oral treatment option for patients living with this rare, debilitating condition who rely on injectable enzyme replacement therapy.”
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
Novel boron-based oral ENPP1 inhibitor advances into development
Get started
Create a free account to read the full story.